Obesave Tablet contains Cetilistat 120 mg, an anti-obesity agent indicated for the management of obesity in conjunction with a reduced-calorie diet and increased physical activity. Cetilistat is a selective and reversible inhibitor of pancreatic lipase, the enzyme responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By inhibiting pancreatic lipase, Cetilistat reduces the absorption of dietary fats, thereby promoting weight loss and improving associated metabolic parameters. Obesave Tablet is prescribed for patients with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or greater who have obesity-related risk factors such as hypertension, type 2 diabetes mellitus, or dyslipidemia. Clinical studies have demonstrated that Cetilistat significantly reduces body weight, waist circumference, and improves lipid profiles when used as part of a comprehensive weight management program. The medication is generally well tolerated; however, patients may experience gastrointestinal side effects including oily spotting, flatulence, and fecal urgency, which are typically mild to moderate and tend to decrease over time. Obesave Tablet should be used under medical supervision with regular monitoring of nutritional status and adherence to lifestyle modifications to achieve optimal therapeutic outcomes.